Proteomics discovery of radioresistant cancer biomarkers for radiotherapy

Lei Chang, Peter Graham, Jingli Hao, Joseph Bucci, David Malouf, David Gillatt, Yong Li*

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)


Radiotherapy (RT) is one of the most important strategies in cancer treatment. Radioresistance is a major challenge to RT and results in locoregional recurrence and metastasis. Thus, there is a great interest in investigating biomarkers to distinguish radiosensitive from radioresistant (RR) cancer patients. The development of proteomic techniques has sparked new searches for novel proteins for cancer biomarker discovery. Modern proteomic techniques allow for a high-throughput analysis of samples with the visualization and quantification of thousands of potential protein and peptide markers. The discovery of RR biomarkers can provide a clue for predicting RT response and discover therapeutic targets for developing personalised medicine of individual patients. In the past decade, emerging advanced proteomic technologies have been performed to identify radiation-related biomarkers in human cancers. This review discusses the mass spectrometry (MS)-based proteomic techniques in RR cancer biomarker discovery, summarises RR biomarkers identified in cancers from proteomics-based findings and explores potential values of RR biomarkers for future clinical trials.

Original languageEnglish
Pages (from-to)289-297
Number of pages9
JournalCancer Letters
Issue number2
Publication statusPublished - 28 Dec 2015

Fingerprint Dive into the research topics of 'Proteomics discovery of radioresistant cancer biomarkers for radiotherapy'. Together they form a unique fingerprint.

  • Cite this